Toggle light / dark theme

For the first time in Israel, a doctor at Beilinson Hospital in Petah Tikva has used a da Vinci robot to perform the complex surgery of untrapping a man’s ureter from behind his vena cava — the largest vein in the body that carries blood to the heart from other areas.

Last month, a 41-year-old patient checked in to Beilinson suffering from the effects of retrocaval ureter, a ureter that abnormally encircles the inferior vena cava. Only one in 1500 people are born with this deformity, which worsens over decades until eventually it leads to sepsis.

With a retrocaval ureter, the ureter passes behind the large vein instead of in front of it or right by it. The only way to cure the person is to perform a complex operation to move the ureter.

Usually “open” surgery is performed, meaning the patient is cut open. But Dr. Shay Golan, head of the Urologic Oncology Service at Beilinson, decided to try something new and, for the first time in Israel, a robot performed the surgery in 50 minutes, making only three very small incisions (each less than 1 centimeter) in his belly and without any blood loss.


Dr. Shay Golan, head of the Urologic Oncology Service at Beilinson Hospital, decided to try something new and, for the first time in Israel, a robot performed the surgery in 50 minutes.

High-energy #lasers are moving quickly from prototype to deployment for the #USArmy and #USNavy. We’ve helped make that happen.


A brief history of high-energy lasers.

The U.S. military has had electromagnetic spectrum weapons in mind since the 1960s. Throughout the 1980s, industry and military laid the groundwork for figuring out how to reach practical power levels, beam control and adaptive optics. The Department of Defense officially recognized lasers as a plausible future weapon in 1999, marking the beginning of formal research and development.

%{[ data-embed-type= image data-embed-id=6105d4fd38fdfbe3338b45e7 data-embed-element= span data-embed-size=320w data-embed-align= left data-embed-alt= Raytheon has installed the prototype High Energy Laser Weapon System (HELWS) aboard a Polaris MRZR all-terrain vehicle to defend military forces from enemy unmanned aircraft. data-embed-src= https://img.militaryaerospace.com/files/base/ebm/mae/image/2…max&w=1440 data-embed-caption= Raytheon has installed the prototype High Energy Laser Weapon System (HELWS) aboard a Polaris MRZR all-terrain vehicle to defend military forces from enemy unmanned aircraft. ]}%However, researchers did demonstrate limited-use lasers earlier than that, with the U.S. Defense Advanced Research Projects Agency (DARPA) firing a 100-kilowatt laser in 1968 and the Navy-ARPA Chemical Laser producing 250 kilowatts in 1975.

When the Human Genome Project reached its ambitious goal of mapping the entire human genome, it seemed the world was entering an era of personalized medicine, where evidence from our own specific genetic material would guide our care.

That was 2003, and nearly a generation after that spectacular collaborative achievement, we are still waiting for that promise to materialize. We may know that a person carries a gene associated with breast cancer, for example, but not whether that person will go on to develop the disease.

New research by McMaster University evolutionary biologist Rama Singh suggests the reason is that there is another, hidden layer that controls how interact, and how the many billions of possible combinations produce certain results. That layer is composed of largely uncharted biochemical pathways that in cells through chemical reactions.

Summary: Combining artificial intelligence, mathematical modeling, and brain imaging data, researchers shed light on the neural processes that occur when people use mental abstraction.

Source: UCL

By using a combination of mathematical modeling, machine learning and brain imaging technology, researchers have discovered what happens in the brain when people use mental abstractions.

Modified RNA CRISPR boosts gene knockdown in human cells.


In the latest of ongoing efforts to expand technologies for modifying genes and their expression, researchers in the lab of Neville Sanjana, PhD, at the New York Genome Center (NYGC) and New York University (NYU) have developed chemically modified guide RNAs for a CRISPR system that targets RNA instead of DNA. These chemically-modified guide RNAs significantly enhance the ability to target – trace, edit, and/or knockdown – RNA in human cells.

Longevity. Technology: In the study published in Cell Chemical Biology, the research team explores a range of different RNA modifications and details how the modified guides increase efficiencies of CRISPR activity from 2-to 5-fold over unmodified guides. They also show that the optimised chemical modifications extend CRISPR targeting activity from 48 hours to four days.

Increasing the efficiencies and “life” of CRISPR-Cas13 guides is of critical value to researchers and drug developers, allowing for better gene knockdown and more time to study how the gene influences other genes in related pathways.

The researchers worked in collaboration with scientists at Synthego Corporation and New England BioLabs, bringing together a diverse team with expertise in enzyme purification and RNA chemistry. To apply these optimised chemical modifications, the research team targeted cell surface receptors in human T cells from healthy donors and a “universal” segment of the genetic sequence shared by all known variants of the RNA virus SARS-COV-2, which is responsible for the COVID-19 pandemic.